Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.

MLA

Antoniotti, Carlotta, et al. “Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 42, no. 22, Aug. 2024, pp. 2637–44. EBSCOhost, https://doi.org/10.1200/JCO.23.02728.

APA

Antoniotti, C., Rossini, D., Pietrantonio, F., Salvatore, L., Lonardi, S., Tamberi, S., Marmorino, F., Moretto, R., Prisciandaro, M., Tamburini, E., Tortora, G., Passardi, A., Bergamo, F., Raimondi, A., Ritorto, G., Borelli, B., Conca, V., Ugolini, C., Aprile, G., … Cremolini, C. (2024). Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 42(22), 2637–2644. https://doi.org/10.1200/JCO.23.02728

Chicago

Antoniotti, Carlotta, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Sara Lonardi, Stefano Tamberi, Federica Marmorino, et al. 2024. “Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 42 (22): 2637–44. doi:10.1200/JCO.23.02728.